Phosphoproteomic analysis of wild-type and antimony-resistant Leishmania braziliensis lines by 2D-DIGE technology.
Moreira Dde S, Pescher P, Laurent C, Lenormand P, Späth GF, Murta SM.
Proteomics. 2015 Sep;15(17):2999-3019. doi: 10.1002/pmic.201400611. Epub 2015 Jun 17.
Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus.
Torre-Cisneros J, Villanueva JL, Kindelan JM, Jurado R, Sanchez-Guijo P.
Clin Infect Dis. 1993 Oct;17(4):625-7. doi: 10.1093/clinids/17.4.625.
Successful treatment of an antimony-resistant American mucocutaneous leishmaniasis: a case report.
Bottasso O, Cabrini J, Falcoff R, Falcoff E.
Arch Dermatol. 1992 Jul;128(7):996-7.
[A case of antimony resistant kala-azar cured with amphotericin B].
Chen SB, Yang CM, Zhang CJ.
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2007 Jun;25(3):inside front page.
[Infecting glial cells with antimony resistant Leishmania tropica: A new ex-vivo model].
Zorbozan O, Harman M, Evren V, Erdoğan MA, Kılavuz A, Tunalı V, Çavuş İ, Yılmaz Ö, Özbilgin A, Turgay N.
Mikrobiyol Bul. 2018 Jan;52(1):49-55. doi: 10.5578/mb.66350.
Short-Course Treatment With Imipramine Entrapped in Squalene Liposomes Results in Sterile Cure of Experimental Visceral Leishmaniasis Induced by Antimony Resistant Leishmania donovani With Increased Efficacy.
Mukherjee S, Pradhan S, Ghosh S, Sundar S, Das S, Mukherjee B, Roy S.
Front Cell Infect Microbiol. 2020 Nov 10;10:595415. doi: 10.3389/fcimb.2020.595415. eCollection 2020.
Unveiling six potent and highly selective antileishmanial agents via the open source compound collection 'Pathogen Box' against antimony-sensitive and -resistant Leishmania braziliensis.
Souza Silva JA, Tunes LG, Coimbra RS, Ascher DB, Pires DEV, Monte-Neto RL.
Biomed Pharmacother. 2021 Jan;133:111049. doi: 10.1016/j.biopha.2020.111049. Epub 2020 Dec 4.
Clinical healing of antimony-resistant cutaneous or mucocutaneous leishmaniasis following the combined administration of interferon-gamma and pentavalent antimonial compounds.
Falcoff E, Taranto NJ, Remondegui CE, Dedet JP, Canini LM, Ripoll CM, Dimier-David L, Vargas F, Giménez LA, Bernabó JG, et al.
Trans R Soc Trop Med Hyg. 1994 Jan-Feb;88(1):95-7. doi: 10.1016/0035-9203(94)90518-5.
Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B (L-AmpB-LRC) in a child.
Karande SC, Boby KF, Lahiri KR, Jain MK, Kshirsagar NA, Gokhale PC, Pandya SK.
Trop Doct. 1995 Apr;25(2):80-1. doi: 10.1177/004947559502500209.
Successful treatment of antimony-resistant cutaneous leishmaniasis with liposomal amphotericin B.
Torre-Cisneros J, Prada JL, Villanueva JL, Valverde F, Sánchez-Guijó P.
Clin Infect Dis. 1994 Jun;18(6):1024-5. doi: 10.1093/clinids/18.6.1024.
